PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 78.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 613 shares of the biopharmaceutical company’s stock after acquiring an additional 270 shares during the quarter. Smartleaf Asset Management LLC’s holdings in PTC Therapeutics were worth $28,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. State of New Jersey Common Pension Fund D increased its stake in PTC Therapeutics by 7.0% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 56,820 shares of the biopharmaceutical company’s stock worth $2,108,000 after buying an additional 3,727 shares during the period. Los Angeles Capital Management LLC increased its stake in PTC Therapeutics by 40.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 15,130 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 4,325 shares during the period. KBC Group NV increased its stake in PTC Therapeutics by 29.2% during the 3rd quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 504 shares during the period. Thrivent Financial for Lutherans purchased a new stake in PTC Therapeutics during the 3rd quarter worth $1,450,000. Finally, Quest Partners LLC increased its stake in PTC Therapeutics by 433.9% during the 3rd quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock worth $830,000 after buying an additional 18,171 shares during the period.

PTC Therapeutics Stock Up 1.9 %

PTC Therapeutics stock opened at $53.61 on Thursday. The firm has a 50-day moving average price of $48.31 and a two-hundred day moving average price of $43.31. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of -9.03 and a beta of 0.66. PTC Therapeutics, Inc. has a 52-week low of $24.00 and a 52-week high of $55.60.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PTCT shares. Barclays lifted their price target on shares of PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $70.00 price target (up previously from $67.00) on shares of PTC Therapeutics in a research note on Friday, March 7th. Scotiabank assumed coverage on shares of PTC Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $55.00 target price for the company. Wells Fargo & Company boosted their target price on shares of PTC Therapeutics from $56.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 26th. Finally, Royal Bank of Canada boosted their target price on shares of PTC Therapeutics from $60.00 to $63.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $63.54.

Insider Buying and Selling at PTC Therapeutics

In other news, CAO Christine Marie Utter sold 879 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $44,037.90. Following the completion of the transaction, the chief accounting officer now directly owns 63,442 shares in the company, valued at $3,178,444.20. This trade represents a 1.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Allan Steven Jacobson sold 1,230 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $51.52, for a total transaction of $63,369.60. Following the completion of the transaction, the director now owns 19,118 shares of the company’s stock, valued at $984,959.36. This trade represents a 6.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,870 shares of company stock valued at $1,075,657 in the last ninety days. Company insiders own 5.50% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.